InvestorsObserver is giving Nabriva Therapeutics PLC - ADR (NBRV) an Analyst Rating Rank of 34, meaning NBRV is ranked higher by analysts than 34% of stocks. The average price target for NBRV is $8 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating NBRV a Buy today. Find out what this means to you and get the rest of the rankings on NBRV!